BACKGROUND: Vascular-related toxicities have been reported among survivors of Hodgkin lymphoma (HL), but their genesis is not well understood. PROCEDURE: Fasting blood samples from 25 previously irradiated HL survivors were analyzed for biomarkers that can reveal underlying inflammation and/or endothelial cell activation: high-sensitivity C-reactive protein (hsCRP), triglycerides, total cholesterol, high-density lipoprotein (HDL), apolipoprotein ß, lipoprotein (a), fibrinogen, circulating endothelial cells (CECs), and vascular cell adhesion molecule-1 (VCAM-1) expression. Values were compared to subjects in the Coronary Artery Risk Development in Young Adults (CARDIA) study. CECs and VCAM-1 were compared to healthy controls. RESULTS: Survivors (76% male), median age 17.6 years (5-33) at diagnosis, 33.0 years (19-55) at follow-up, included stages IA (n = 6), IIA (n = 10), IIB (n = 2), IIIA (n = 4), and IVA (n = 3) patients. Twenty-four received at least chest radiation therapy (RT) (median dose 3,150 cGy; range: 175-4,650 cGy), one received neck only; 14 (56%) had a history of anthracycline exposure (median dose: 124 mg/m(2) range: 63-200 mg/m2). Compared to CARDIA subjects, mean hsCRP (3.0 mg/L ± 2.0 vs. 1.6 ± 1.9), total cholesterol (194.1 mg/dl ± 33.2 vs. 179.4 ± 32.9), lipoprotein (a) (34.2 mg/dl ± 17.5 vs. 13.8 ± 17.5), and fibrinogen (342.0 mg/dl ± 49.1 vs. 252.6 ± 48.4) were significantly elevated. CECs (2.3 cells/ml ± 1.5 vs. 0.34 ± 1.4) were significantly elevated compared to controls. No difference in VCAM-1 expression (51.1% ± 36.8 vs. 42.3 ± 35.6) was detected. CONCLUSION: HL survivors exposed to RT have evidence of vascular inflammation, dyslipidemia, and injury suggestive of early atherogenesis.
BACKGROUND: Vascular-related toxicities have been reported among survivors of Hodgkin lymphoma (HL), but their genesis is not well understood. PROCEDURE: Fasting blood samples from 25 previously irradiated HL survivors were analyzed for biomarkers that can reveal underlying inflammation and/or endothelial cell activation: high-sensitivity C-reactive protein (hsCRP), triglycerides, total cholesterol, high-density lipoprotein (HDL), apolipoprotein ß, lipoprotein (a), fibrinogen, circulating endothelial cells (CECs), and vascular cell adhesion molecule-1 (VCAM-1) expression. Values were compared to subjects in the Coronary Artery Risk Development in Young Adults (CARDIA) study. CECs and VCAM-1 were compared to healthy controls. RESULTS: Survivors (76% male), median age 17.6 years (5-33) at diagnosis, 33.0 years (19-55) at follow-up, included stages IA (n = 6), IIA (n = 10), IIB (n = 2), IIIA (n = 4), and IVA (n = 3) patients. Twenty-four received at least chest radiation therapy (RT) (median dose 3,150 cGy; range: 175-4,650 cGy), one received neck only; 14 (56%) had a history of anthracycline exposure (median dose: 124 mg/m(2) range: 63-200 mg/m2). Compared to CARDIA subjects, mean hsCRP (3.0 mg/L ± 2.0 vs. 1.6 ± 1.9), total cholesterol (194.1 mg/dl ± 33.2 vs. 179.4 ± 32.9), lipoprotein (a) (34.2 mg/dl ± 17.5 vs. 13.8 ± 17.5), and fibrinogen (342.0 mg/dl ± 49.1 vs. 252.6 ± 48.4) were significantly elevated. CECs (2.3 cells/ml ± 1.5 vs. 0.34 ± 1.4) were significantly elevated compared to controls. No difference in VCAM-1 expression (51.1% ± 36.8 vs. 42.3 ± 35.6) was detected. CONCLUSION: HL survivors exposed to RT have evidence of vascular inflammation, dyslipidemia, and injury suggestive of early atherogenesis.
Authors: M I Cybulsky; K Iiyama; H Li; S Zhu; M Chen; M Iiyama; V Davis; J C Gutierrez-Ramos; P W Connelly; D S Milstone Journal: J Clin Invest Date: 2001-05 Impact factor: 14.808
Authors: Alexander Woywodt; Johanna Scheer; Lothar Hambach; Stefanie Buchholz; Arnold Ganser; Hermann Haller; Bernd Hertenstein; Marion Haubitz Journal: Blood Date: 2004-01-08 Impact factor: 22.113
Authors: J P Neglia; D L Friedman; Y Yasui; A C Mertens; S Hammond; M Stovall; S S Donaldson; A T Meadows; L L Robison Journal: J Natl Cancer Inst Date: 2001-04-18 Impact factor: 11.816
Authors: James G Gurney; Nina S Kadan-Lottick; Roger J Packer; Joseph P Neglia; Charles A Sklar; Judy A Punyko; Marilyn Stovall; Yutaka Yasui; H Stacy Nicholson; Suzanne Wolden; Dawn E McNeil; Ann C Mertens; Leslie L Robison Journal: Cancer Date: 2003-02-01 Impact factor: 6.921
Authors: Kirsten K Ness; Kendra E Jones; Webb A Smith; Sheri L Spunt; Carmen L Wilson; Gregory T Armstrong; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; James G Gurney Journal: Arch Phys Med Rehabil Date: 2013-03-26 Impact factor: 3.966
Authors: Merry L Lindsey; Richard A Lange; Helen Parsons; Thomas Andrews; Gregory J Aune Journal: Am J Physiol Heart Circ Physiol Date: 2014-09-12 Impact factor: 4.733
Authors: Daniel A Mulrooney; Kirsten K Ness; Sujuan Huang; Anna Solovey; Robert P Hebbel; James D Neaton; Denis R Clohisy; Aaron S Kelly; Joseph P Neglia Journal: Pediatr Blood Cancer Date: 2013-05-30 Impact factor: 3.167
Authors: Daniel Mathias; Ronald E J Mitchel; Mirela Barclay; Heather Wyatt; Michelle Bugden; Nicholas D Priest; Stewart C Whitman; Markus Scholz; Guido Hildebrandt; Manja Kamprad; Annegret Glasow Journal: PLoS One Date: 2015-03-23 Impact factor: 3.240